Journal of Molecular Endocrinology

References

1. ↵
   1. Armagan G,
   2. Kanit L,
   3. Terek CM,
   4. Sozmen EY,
   5. Yalcin A

   2009 The levels of glutathione and nitrite–nitrate and the expression of Bcl-2 mRNA in ovariectomized rats treated by raloxifene against kainic acid. International Journal of Neuroscience 119 227–239.doi:10.1080/00207450802330959.
2. ↵
   1. Azcoitia I,
   2. Moreno A,
   3. Carrero P,
   4. Palacios S,
   5. Garcia-Segura LM

   2006 Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecological Endocrinology 22 63–69.doi:10.1080/09513590500519161.
3. ↵
   1. Barreto G,
   2. Santos-Galindo M,
   3. Diz-Chaves Y,
   4. Pernía O,
   5. Carrero P,
   6. Azcoitia I,
   7. Garcia-Segura LM

   2009 Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. Endocrinology 150 5010–5015.doi:10.1210/en.2009-0352.
4. ↵
   1. Barrett-Connor E,
   2. Cox DA,
   3. Song J,
   4. Mitlak B,
   5. Mosca L,
   6. Grady D

   2009 Raloxifene and risk for stroke based on the framingham stroke risk score. American Journal of Medicine 122 754–761.doi:10.1016/j.amjmed.2009.01.033.
5. ↵
   1. Bebo BF,
   2. Dehghani B,
   3. Foster S,
   4. Kurniawan A,
   5. Lopez FJ,
   6. Sherman LS

   2009 Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 57 777–790.doi:10.1002/glia.20805.
6. ↵
   1. Belandia B,
   2. Parker MG

   2003 Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114 277–280.doi:10.1016/S0092-8674(03)00599-3.
7. ↵
   1. Benvenuti S,
   2. Luciani P,
   3. Vannelli GB,
   4. Gelmini S,
   5. Franceschi E,
   6. Serio M,
   7. Peri A

   2005 Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. Journal of Clinical Endocrinology and Metabolism 90 1775–1782.doi:10.1210/jc.2004-0066.
8. ↵
   1. Bernardi F,
   2. Pluchino N,
   3. Stomati M,
   4. Pieri M,
   5. Genazzani AR

   2003 CNS: sex steroids and SERMs. Annals of the New York Academy of Sciences 997 378–388.doi:10.1196/annals.1290.041.
9. ↵
   1. Biewenga E,
   2. Cabell L,
   3. Audesirk T

   2005 Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress. Neuroscience Letters 373 179–183.doi:10.1016/j.neulet.2004.09.067.
10. ↵
    1. Bourque M,
    2. Liu B,
    3. Dluzen DE,
    4. Di Paolo T

    2007 Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochemical Pharmacology 74 1413–1423.doi:10.1016/j.bcp.2007.07.009.
11. ↵
    1. Breuer B,
    2. Anderson R

    2000 The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women's Health 31 71–85.doi:10.1300/J013v31n01_05.
12. ↵
    1. Brinton RD

    2004 Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. Journal of Alzheimer's Disease 6 (6 Supplement) S27–S35.
13. ↵
    1. Brzozowski AM,
    2. Pike AC,
    3. Dauter Z,
    4. Hubbard RE,
    5. Bonn T,
    6. Engstrom O,
    7. Ohman L,
    8. Greene GL,
    9. Gustafsson JA,
    10. Carlquist M

    1997 Molecular basis of agonism and antagonism in the estrogen receptor. Nature 389 753–758.doi:10.1038/39645.
14. ↵
    1. Callier S,
    2. Morissette M,
    3. Grandbois M,
    4. Pelaprat D,
    5. Di Paolo T

    2001 Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 131–138.doi:10.1002/syn.1067.
15. ↵
    1. Carranza-Lira S,
    2. MacGregor-Gooch AL,
    3. Sarachaga-Osterwalder M

    2004 Mood modifications with raloxifene and continuous estrogen plus progestin hormone therapy. International Journal of Fertility and Women's Medicine 49 120–122.
16. ↵
    1. Cerciat M,
    2. Unkila M,
    3. Garcia-Segura LM,
    4. Arevalo MA

    2010 Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-γ-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 58 93–102.doi:10.1002/glia.20904.
17. ↵
    1. Ciriza I,
    2. Carrero P,
    3. Azcoitia I,
    4. Lundeen SG,
    5. Garcia-Segura LM

    2004 Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. Journal of Neurobiology 61 209–221.doi:10.1002/neu.20043.
18. ↵
    1. Cyr M,
    2. Landry M,
    3. Di Paolo T

    2000 Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 23 69–78.doi:10.1016/S0893-133X(00)00085-3.
19. ↵
    1. Debess J,
    2. Riis JØ,
    3. Engebjerg MC,
    4. Ewertz M

    2010 Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Research and Treatment 121 91–100.doi:10.1007/s10549-010-0756-8.
20. ↵
    1. Dhandapani KM,
    2. Brann DW

    2002 Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biology of Reproduction 67 1379–1385.doi:10.1095/biolreprod.102.003848.
21. ↵
    1. DonCarlos LL,
    2. Azcoitia I,
    3. Garcia-Segura LM

    2009 Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 34 (Supplement 1) S113–S122.doi:10.1016/j.psyneuen.2009.04.012.
22. ↵
    1. Dowers TS,
    2. Qin ZH,
    3. Thatcher GR,
    4. Bolton JL

    2006 Bioactivation of selective estrogen receptor modulators (SERMs). Chemical Research in Toxicology 19 1125–1137.doi:10.1021/tx060126v.
23. ↵
    1. Du B,
    2. Ohmichi M,
    3. Takahashi K,
    4. Kawagoe J,
    5. Ohshima C,
    6. Igarashi H,
    7. Mori-Abe A,
    8. Saitoh M,
    9. Ohta T,
    10. Ohishi A,
    11. et al.

    2004 Both estrogen and raloxifene protect against β-amyloid-induced neurotoxicity in estrogen receptor α-transfected PC12 cells by activation of telomerase activity via Akt cascade. Journal of Endocrinology 183 605–615.doi:10.1677/joe.1.05775.
24. ↵
    1. Einat H,
    2. Yuan P,
    3. Szabo ST,
    4. Dogra S,
    5. Manji HK

    2007 Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55 123–131.doi:10.1159/000106054.
25. ↵
    1. Feng Y,
    2. Fratkins JD,
    3. LeBlanc MH

    2004 Treatment with tamoxifen reduces hypoxic-ischemic brain injury in neonatal rats. European Journal of Pharmacology 484 65–74.doi:10.1016/j.ejphar.2003.10.048.
26. ↵
    1. Florio P,
    2. Quirici B,
    3. Casarosa E,
    4. Lombardi I,
    5. Luisi M,
    6. Genazzani AD,
    7. Petraglia F,
    8. Gennazzani AR

    2001 Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecological Endocrinology 15 359–366.doi:10.1080/gye.15.5.359.366.
27. ↵
    1. Garcia-Segura LM,
    2. Balthazart J

    2009 Steroids and neuroprotection: new advances. Frontiers in Neuroendocrinology 30 v–ix.doi:10.1016/j.yfrne.2009.04.006.
28. ↵
    1. Genazzani AR,
    2. Bernardi F,
    3. Stomati M,
    4. Rubino S,
    5. Giardina L,
    6. Luisi S,
    7. Monteleone P,
    8. Genazzani AD,
    9. Luisi M,
    10. Petraglia F

    1999 Raloxifene analog LY 117018 effects on central and peripheral β-endorphin. Gynecological Endocrinology 13 249–258.doi:10.3109/09513599909167563.
29. ↵
    1. Genazzani AR,
    2. Bernardi F,
    3. Stomati M,
    4. Monteleone P,
    5. Luisi S,
    6. Rubino S,
    7. Farzati A,
    8. Casarosa E,
    9. Luisi M,
    10. Petraglia F

    2000 Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 72 162–170.doi:10.1159/000054583.
30. ↵
    1. Genazzani AR,
    2. Lombardi I,
    3. Borgioli G,
    4. di Buono I,
    5. Casarosa E,
    6. Gambacciani M,
    7. Palumbo M,
    8. Genazzani AD,
    9. Luisi M

    2003 Adrenal function under long-term raloxifene administration increases β-endorphin and tetrahydroprogesterone. Gynecological Endocrinology 17 159–168.
31. ↵
    1. Goekoop R,
    2. Duschek EJ,
    3. Knol DL,
    4. Barkhof F,
    5. Netelenbos C,
    6. Scheltens P,
    7. Rombouts SA

    2005 Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. NeuroImage 25 63–75.doi:10.1016/j.neuroimage.2004.11.012.
32. ↵
    1. Goekoop R,
    2. Barkhof F,
    3. Duschek EJ,
    4. Netelenbos C,
    5. Knol DL,
    6. Scheltens P,
    7. Rombouts SA

    2006 Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology 31 1508–1518.doi:10.1038/sj.npp.1300956.
33. ↵
    1. Grandbois M,
    2. Morissette M,
    3. Callier S,
    4. Di Paolo T

    2000 Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 11 343–346.doi:10.1097/00001756-200002070-00024.
34. ↵
    1. Green PS,
    2. Yang SH,
    3. Nilsson KR,
    4. Kumar AS,
    5. Covey DF,
    6. Simpkins JW

    2001 The nonfeminizing enantiomer of 17β-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology 142 400–406.doi:10.1210/en.142.1.400.
35. ↵
    1. Grigoriadis S,
    2. Kennedy SH,
    3. Srinivisan J,
    4. McIntyre RS,
    5. Fulton K

    2005 Antidepressant augmentation with raloxifene. Journal of Clinical Psychopharmacology 25 96–98.doi:10.1097/01.jcp.0000150230.07243.52.
36. ↵
    1. Jacobsen DE,
    2. Samson MM,
    3. Emmelot-Vonk MH,
    4. Verhaar HJ

    2010 Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause 17 309–314.doi:10.1097/gme.0b013e3181bd54df.
37. ↵
    1. Jung ME,
    2. Wilson AM,
    3. Simpkins JW

    2006 A nonfeminizing estrogen analog protects against ethanol withdrawal toxicity in immortalized hippocampal cells. Journal of Pharmacology and Experimental Therapeutics 319 543–550.doi:10.1124/jpet.106.103630.
38. ↵
    1. Kimelberg HK

    2008 Tamoxifen as a powerful neuroprotectant in experimental stroke and implications for human stroke therapy. Recent Patents on CNS Drug Discovery 3 104–108.doi:10.2174/157488908784534603.
39. ↵
    1. Kimelberg HK,
    2. Jin Y,
    3. Charniga C,
    4. Feustel PJ

    2003 Neuroprotective activity of tamoxifen in permanent focal ischemia. Journal of Neurosurgery 99 138–142.doi:10.3171/jns.2003.99.1.0138.
40. ↵
    1. Klinge CM

    2000 Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 227–251.doi:10.1016/S0039-128X(99)00107-5.
41. ↵
    1. Kokiko ON,
    2. Murashov AK,
    3. Hoane MR

    2006 Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behavioural Brain Research 170 233–240.doi:10.1016/j.bbr.2006.02.026.
42. ↵
    1. Konyalioglu S,
    2. Durmaz G,
    3. Yalcin A

    2007 The potential antioxidant effect of raloxifene treatment: a study on heart, liver and brain cortex of ovariectomized female rats. Cell Biochemistry and Function 25 259–266.doi:10.1002/cbf.1328.
43. ↵
    1. Kulkarni J,
    2. Garland KA,
    3. Scaffidi A,
    4. Headey B,
    5. Anderson R,
    6. de Castella A,
    7. Fitzgerald P,
    8. Davis SR

    2006 A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31 543–547.doi:10.1016/j.psyneuen.2005.11.001.
44. ↵
    1. Kulkarni J,
    2. Gurvich C,
    3. Lee SJ,
    4. Gilbert H,
    5. Gavrilidis E,
    6. de Castella A,
    7. Berk M,
    8. Dodd S,
    9. Fitzgerald PB,
    10. Davis SR

    2010 Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35 1142–1147.doi:10.1016/j.psyneuen.2010.01.014.
45. ↵
    1. Landry M,
    2. Levesque D,
    3. Di Paolo T

    2002 Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76 214–222.doi:10.1159/000065951.
46. ↵
    1. Latourelle JC,
    2. Dybdahl M,
    3. Destefano AL,
    4. Myers RH,
    5. Lash TL

    2010 Risk of Parkinson's disease after tamoxifen treatment. BMC Neurology 10 23doi:10.1186/1471-2377-10-23.
47. ↵
    1. Lee ES,
    2. Sidoryk M,
    3. Jiang H,
    4. Yin Z,
    5. Aschner M

    2009a Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. Journal of Neurochemistry 110 530–544.doi:10.1111/j.1471-4159.2009.06105.x.
48. ↵
    1. Lee ES,
    2. Yin Z,
    3. Milatovic D,
    4. Jiang H,
    5. Aschner M

    2009b Estrogen and tamoxifen protect against Mn-induced toxicity in rat cortical primary cultures of neurons and astrocytes. Toxicological Sciences 110 156–167.doi:10.1093/toxsci/kfp081.
49. ↵
    1. Lei DL,
    2. Long JM,
    3. Hengemihle J,
    4. O'Neill J,
    5. Manaye KF,
    6. Ingram DK,
    7. Mouton PR

    2003 Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience 121 659–666.doi:10.1016/S0306-4522(03)00245-8.
50. ↵
    1. Liu R,
    2. Yang SH,
    3. Perez E,
    4. Yi KD,
    5. Wu SS,
    6. Eberst K,
    7. Prokai L,
    8. Prokai-Tatrai K,
    9. Cai ZY,
    10. Covey DF,
    11. et al.

    2002 Neuroprotective effects of a novel non-receptor-binding estrogen analogue: in vitro and in vivo analysis. Stroke 33 2485–2491.doi:10.1161/01.STR.0000030317.43597.C8.
51. ↵
    1. Liu JL,
    2. Tian DS,
    3. Li ZW,
    4. Qu WS,
    5. Zhan Y,
    6. Xie MJ,
    7. Yu ZY,
    8. Wang W,
    9. Wu G

    2010 Tamoxifen alleviates irradiation-induced brain injury by attenuating microglial inflammatory response in vitro and in vivo. Brain Research 1316 101–111.doi:10.1016/j.brainres.2009.12.055.
52. ↵
    1. McKenna NP,
    2. O'Malley BO

    2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 465–474.doi:10.1016/S0092-8674(02)00641-4.
53. ↵
    1. McMurray R,
    2. Islamov R,
    3. Murashov AK

    2003 Raloxifene analog LY117018 enhances the regeneration of sciatic nerve in ovariectomized female mice. Brain Research 980 140–145.doi:10.1016/S0006-8993(03)02984-6.
54. ↵
    1. Mehta SH,
    2. Dhandapani KM,
    3. De Sevilla LM,
    4. Webb RC,
    5. Mahesh VB,
    6. Brann DW

    2003 Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology 77 44–50.doi:10.1159/000068332.
55. ↵
    1. Mickley KR,
    2. Dluzen DE

    2004 Dose–response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice. Neuroendocrinology 79 305–316.doi:10.1159/000079710.
56. ↵
    1. Moreira PI,
    2. Custódio JB,
    3. Oliveira CR,
    4. Santos MS

    2004 Hydroxytamoxifen protects against oxidative stress in brain mitochondria. Biochemical Pharmacology 68 195–204.doi:10.1016/j.bcp.2004.03.019.
57. ↵
    1. Moreira PI,
    2. Custódio JB,
    3. Oliveira CR,
    4. Santos MS

    2005 Brain mitochondrial injury induced by oxidative stress-related events is prevented by tamoxifen. Neuropharmacology 48 435–447.doi:10.1016/j.neuropharm.2004.10.012.
58. ↵
    1. Morissette M,
    2. Al Sweidi S,
    3. Callier S,
    4. Di Paolo T

    2008 Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Molecular and Cellular Endocrinology 290 60–69.doi:10.1016/j.mce.2008.04.008.
59. ↵
    1. Mosca L,
    2. Grady D,
    3. Barrett-Connor E,
    4. Collins P,
    5. Wenger N,
    6. Abramson BL,
    7. Paganini-Hill A,
    8. Geiger MJ,
    9. Dowsett SA,
    10. Amewou-Atisso M,
    11. et al.

    2009 Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40 147–155.doi:10.1161/STROKEAHA.108.518621.
60. ↵
    1. Neele SJ,
    2. Evertz R,
    3. Genazzani AR,
    4. Luisi M,
    5. Netelenbos C

    2002 Raloxifene treatment increases plasma levels of β-endorphin in postmenopausal women: a randomized, placebo-controlled study. Fertility and Sterility 77 1110–1117.doi:10.1016/S0015-0282(02)03108-4.
61. ↵
    1. Nilsen J,
    2. Mor G,
    3. Naftolin F

    1998 Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 5 211–216.doi:10.1097/00042192-199805040-00005.
62. ↵
    1. Norris JD,
    2. Paige LA,
    3. Christensen DJ,
    4. Chang CY,
    5. Huacani MR,
    6. Fan D,
    7. Hamilton PT,
    8. Fowlkes DM,
    9. McDonnell DP

    1999 Peptide antagonists of the human estrogen receptor. Science 285 744–746.doi:10.1126/science.285.5428.744.
63. ↵
    1. O'Neill K,
    2. Chen S,
    3. Diaz Brinton R

    2004 Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Experimental Neurology 188 268–278.doi:10.1016/j.expneurol.2004.01.014.
64. ↵
    1. Paganini-Hill A,
    2. Clark LJ

    2000 Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment 64 165–176.doi:10.1023/A:1006426132338.
65. ↵
    1. Paige LA,
    2. Christensen DJ,
    3. Grøn H,
    4. Norris JD,
    5. Gottlin EB,
    6. Padilla KM,
    7. Chang CY,
    8. Ballas LM,
    9. Hamilton PT,
    10. McDonnell DP

    1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERb. PNAS 96 3999–4004.doi:10.1073/pnas.96.7.3999.
66. ↵
    1. Palmer JL,
    2. Trotter T,
    3. Joy AA,
    4. Carlson LE

    2008 Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. Journal of Cancer Survivorship 2 275–282.doi:10.1007/s11764-008-0070-1.
67. ↵
    1. Phillips KA,
    2. Ribi K,
    3. Sun Z,
    4. Stephens A,
    5. Thompson A,
    6. Harvey V,
    7. Thürlimann B,
    8. Cardoso F,
    9. Pagani O,
    10. Coates AS,
    11. et al.

    2010 Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1–98 randomized trial. Breast 19 388–395.doi:10.1016/j.breast.2010.03.025.
68. ↵
    1. Rossberg MI,
    2. Murphy SJ,
    3. Traystman RJ,
    4. Hurn PD

    2000 LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Stroke 31 3041–3046.
69. ↵
    1. Sánchez MG,
    2. Bourque M,
    3. Morissette M,
    4. Di Paolo T

    2010 Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neuroscience and Therapeutics 16 e43–e71.doi:10.1111/j.1755-5949.2010.00163.x.
70. ↵
    1. Schilder CM,
    2. Seynaeve C,
    3. Beex LV,
    4. Boogerd W,
    5. Linn SC,
    6. Gundy CM,
    7. Huizenga HM,
    8. Nortier JW,
    9. van de Velde CJ,
    10. van Dam FS,
    11. et al.

    2010 Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology 28 1294–1300.doi:10.1200/JCO.2008.21.3553.
71. ↵
    1. Schreihofer DA,
    2. Redmond L

    2009 Soy phytoestrogens are neuroprotective against stroke-like injury in vitro. Neuroscience 158 602–609.doi:10.1016/j.neuroscience.2008.10.003.
72. ↵
    1. Sharma K,
    2. Mehra RD

    2008 Long-term administration of estrogen or tamoxifen to ovariectomized rats affords neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and Bax. Brain Research 1204 1–15.doi:10.1016/j.brainres.2008.01.080.
73. ↵
    1. Sharma K,
    2. Mehra RD,
    3. Dhar P,
    4. Vij U

    2007 Chronic exposure to estrogen and tamoxifen regulates synaptophysin and phosphorylated cAMP response element-binding (CREB) protein expression in CA1 of ovariectomized rat hippocampus. Brain Research 1132 10–19.doi:10.1016/j.brainres.2006.11.027.
74. ↵
    1. Shilling V,
    2. Jenkins V,
    3. Fallowfield L,
    4. Howell T

    2003 The effects of hormone therapy on cognition in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 86 405–412.doi:10.1016/j.jsbmb.2003.07.001.
75. ↵
    1. Simpkins JW,
    2. Wen Y,
    3. Perez E,
    4. Yang S,
    5. Wang X

    2005 Role of nonfeminizing estrogens in brain protection from cerebral ischemia: an animal model of Alzheimer's disease neuropathology. Annals of the New York Academy of Sciences 1052 233–242.doi:10.1196/annals.1347.019.
76. ↵
    1. Smith LJ,
    2. Henderson JA,
    3. Abell CW,
    4. Bethea CL

    2004 Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 29 2035–2045.doi:10.1038/sj.npp.1300510.
77. ↵
    1. Strickler R,
    2. Stovall DW,
    3. Merritt D,
    4. Shen W,
    5. Wong M,
    6. Silfen SL

    2000 Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstetrics and Gynecology 96 359–365.doi:10.1016/S0029-7844(00)00937-6.
78. ↵
    1. Sugiyama N,
    2. Sasayama D,
    3. Amano N

    2007 Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: a case report. Journal of Clinical Psychiatry 68 636–637.doi:10.4088/JCP.v68n0423d.
79. ↵
    1. Suuronen T,
    2. Nuutinen T,
    3. Huuskonen J,
    4. Ojala J,
    5. Thornell A,
    6. Salminen A

    2005 Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflammation Research 54 194–203.doi:10.1007/s00011-005-1343-z.
80. ↵
    1. Tapia-Gonzalez S,
    2. Carrero P,
    3. Pernia O,
    4. Garcia-Segura LM,
    5. Diz-Chaves Y

    2008 Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs. Journal of Endocrinology 198 219–230.doi:10.1677/JOE-07-0294.
81. ↵
    1. Tian DS,
    2. Liu JL,
    3. Xie MJ,
    4. Zhan Y,
    5. Qu WS,
    6. Yu ZY,
    7. Tang ZP,
    8. Pan DJ,
    9. Wang W

    2009 Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. Journal of Neurochemistry 109 1658–1667.doi:10.1111/j.1471-4159.2009.06077.x.
82. ↵
    1. Wakade C,
    2. Khan MM,
    3. De Sevilla LM,
    4. Zhang QG,
    5. Mahesh VB,
    6. Brann DW

    2008 Tamoxifen neuroprotection in cerebral ischemia involves attenuation of kinase activation and superoxide production and potentiation of mitochondrial superoxide dismutase. Endocrinology 149 367–379.doi:10.1210/en.2007-0899.
83. ↵
    1. Walf AA,
    2. Frye CA

    2010 Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats. Behavioural Pharmacology 21 231–240.doi:10.1097/FBP.0b013e32833a5cb0.
84. ↵
    1. Wang X,
    2. Dykens JA,
    3. Perez E,
    4. Liu R,
    5. Yang S,
    6. Covey DF,
    7. Simpkins JW

    2006 Neuroprotective effects of 17β-estradiol and nonfeminizing estrogens against H₂O₂ toxicity in human neuroblastoma SK-N-SH cells. Molecular Pharmacology 70 395–404.doi:10.1124/mol.106.023986.
85. ↵
    1. Wu X,
    2. Glinn MA,
    3. Ostrowski NL,
    4. Su Y,
    5. Ni B,
    6. Cole HW,
    7. Bryant HU,
    8. Paul SM

    1999 Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Research 847 98–104.doi:10.1016/S0006-8993(99)02062-4.
86. ↵
    1. Yaffe K,
    2. Krueger K,
    3. Cummings SR,
    4. Blackwell T,
    5. Henderson VW,
    6. Sarkar S,
    7. Ensrud K,
    8. Grady D

    2005 Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. American Journal of Psychiatry 162 683–690.doi:10.1176/appi.ajp.162.4.683.
87. ↵
    1. Yang SH,
    2. Liu R,
    3. Wu SS,
    4. Simpkins JW

    2003 The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Annals of the New York Academy of Sciences 1007 101–107.doi:10.1196/annals.1286.010.
88. ↵
    1. Zarate CA,
    2. Singh JB,
    3. Carlson PJ,
    4. Quiroz J,
    5. Jolkovsky L,
    6. Luckenbaugh DA,
    7. Manji HK

    2007 Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 9 561–570.doi:10.1111/j.1399-5618.2007.00530.x.
89. ↵
    1. Zhang Y,
    2. Milatovic D,
    3. Aschner M,
    4. Feustel PJ,
    5. Kimelberg HK

    2007 Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Experimental Neurology 204 819–827.doi:10.1016/j.expneurol.2007.01.015.
90. ↵
    1. Zhang H,
    2. Xie M,
    3. Schools GP,
    4. Feustel PF,
    5. Wang W,
    6. Lei T,
    7. Kimelberg HK,
    8. Zhou M

    2009 Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model. Brain Research 1247 196–211.doi:10.1016/j.brainres.2008.10.015.
91. ↵
    1. Zhao L,
    2. O'Neill K,
    3. Diaz Brinton R

    2005 Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Research. Brain Research Reviews 49 472–493.doi:10.1016/j.brainresrev.2005.01.009.
92. ↵
    1. Zhao L,
    2. Jin C,
    3. Mao Z,
    4. Gopinathan MB,
    5. Rehder K,
    6. Brinton RD

    2007 Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator – a hybrid structure of 17β-estradiol and vitamin E in hippocampal neurons. Journal of Medicinal Chemistry 50 4471–4481.doi:10.1021/jm070546x.